Your browser doesn't support javascript.
loading
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
Goyal, Lipika; Saha, Supriya K; Liu, Leah Y; Siravegna, Giulia; Leshchiner, Ignaty; Ahronian, Leanne G; Lennerz, Jochen K; Vu, Phuong; Deshpande, Vikram; Kambadakone, Avinash; Mussolin, Benedetta; Reyes, Stephanie; Henderson, Laura; Sun, Jiaoyuan Elisabeth; Van Seventer, Emily E; Gurski, Joseph M; Baltschukat, Sabrina; Schacher-Engstler, Barbara; Barys, Louise; Stamm, Christelle; Furet, Pascal; Ryan, David P; Stone, James R; Iafrate, A John; Getz, Gad; Porta, Diana Graus; Tiedt, Ralph; Bardelli, Alberto; Juric, Dejan; Corcoran, Ryan B; Bardeesy, Nabeel; Zhu, Andrew X.
Afiliación
  • Goyal L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Saha SK; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Liu LY; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Siravegna G; Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.
  • Leshchiner I; Department of Oncology, University of Torino, Torino, Italy.
  • Ahronian LG; Fondazione Italiana per la Ricerca sul Cancro (FIRC) Institute of Molecular Oncology (IFOM), Milano, Italy.
  • Lennerz JK; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.
  • Vu P; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Deshpande V; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Kambadakone A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Mussolin B; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Reyes S; Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
  • Henderson L; Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.
  • Sun JE; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Van Seventer EE; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Gurski JM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Baltschukat S; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Schacher-Engstler B; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Barys L; Novartis Institutes for BioMedical Research, Oncology Translational Research, Basel, Switzerland.
  • Stamm C; Novartis Institutes for BioMedical Research, Oncology Translational Research, Basel, Switzerland.
  • Furet P; Novartis Institutes for BioMedical Research, Oncology Translational Research, Basel, Switzerland.
  • Ryan DP; Novartis Institutes for BioMedical Research, Oncology Translational Research, Basel, Switzerland.
  • Stone JR; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Basel, Switzerland.
  • Iafrate AJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Getz G; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Porta DG; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Tiedt R; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Bardelli A; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.
  • Juric D; Novartis Institutes for BioMedical Research, Oncology Translational Research, Basel, Switzerland.
  • Corcoran RB; Novartis Institutes for BioMedical Research, Oncology Translational Research, Basel, Switzerland.
  • Bardeesy N; Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.
  • Zhu AX; Department of Oncology, University of Torino, Torino, Italy.
Cancer Discov ; 7(3): 252-263, 2017 03.
Article en En | MEDLINE | ID: mdl-28034880
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Pirimidinas / Neoplasias de los Conductos Biliares / Colangiocarcinoma / Resistencia a Antineoplásicos / Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Discov Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Pirimidinas / Neoplasias de los Conductos Biliares / Colangiocarcinoma / Resistencia a Antineoplásicos / Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Discov Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos